Rofecoxib
- Generic Name
- Rofecoxib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14O4S
- CAS Number
- 162011-90-7
- Unique Ingredient Identifier
- 0QTW8Z7MCR
- Background
Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived...
- Indication
For the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras.
- Associated Conditions
- -
- Associated Therapies
- -
CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen
- Conditions
- Interventions
- First Posted Date
- 2013-01-08
- Last Posted Date
- 2013-01-08
- Lead Sponsor
- Hospital Universitario Pedro Ernesto
- Target Recruit Count
- 22
- Registration Number
- NCT01762891
Coxib-inhibition of Duodenal Polyp Growth in FAP
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2011-07-06
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT00844727
- Locations
- 🇳🇴
Dept of Medicine, Rikshospitalet, Oslo, Norway
A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2018-11-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 45
- Registration Number
- NCT00657449
- Locations
- 🇧🇷
Instituto Ortopedico de Goiania, Goiania, Goias, Brazil
🇧🇷Grupo Hospitalar Conceiçao, Porto Alegre, RS, Brazil
🇧🇷Hospital Geral do Grajau, São Paulo, SP, Brazil
Safety of Lumiracoxib in Patients With Osteoarthritis
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2008-03-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 309
- Registration Number
- NCT00637949
Barrett's Esophagus - 315 - 3 Way Cross Over
- Conditions
- Interventions
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT00637988
A Four-Week Study Comparing Acetaminophen Extended Release and Rofecoxib in the Treatment of Osteoarthritis of the Knee
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2011-08-22
- Target Recruit Count
- 403
- Registration Number
- NCT00568295
Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 400
- Registration Number
- NCT00385606
- Locations
- 🇮🇹
Ospedale S. Paolo, Milano, MI, Italy
🇮🇹Ospedale Umberto di Frosinone, Frosinone, FR, Italy
🇮🇹Ospedale L. Sacco, Milano, Italy
An End to the Yom Kippur (and Ramadan) Headache
- Conditions
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2006-01-27
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 220
- Registration Number
- NCT00263094
- Locations
- 🇮🇱
Sheba Medical Center, Tel Hashomer, Israel
Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)
- Conditions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 15000
- Registration Number
- NCT00060476
Rofecoxib After Surgery in Treating Patients With Stage II or Stage III Colorectal Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Cancer Research Campaign Clinical Trials Centre
- Registration Number
- NCT00031863
- Locations
- 🇬🇧
Radcliffe Infirmary NHS Trust, Oxford, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.